YESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY

Stock News

2025/08/29

YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1101906794"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101906794\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101906794?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101906794","market":"sg","top_or_hot":-1,"title":"YESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY","media":"Stock News","content":"<p>YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>YESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-29 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1222","symbol_name":"医疗保健用品","start_time":0,"source_url":"","article_id":"1101906794","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101906794","pubTimestamp":1756474233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1222":"医疗保健用品","02393":"巨星医疗控股"},"translate_title":"巨星健康(02393)公布中期业绩拥有人应占溢利576.1万港元同比下跌99.47%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02393":1},"content_text":"YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}